Saxenda Injection, Solution
Product Images NDC 50090-4257

Product Visual Gallery

This gallery contains 45 technical images submitted to the FDA as part of the official labeling for Saxenda (NDC 50090-4257). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image 01)

Chemical structure diagram of liraglutide, showing a sequence of amino acids as labeled circles, including an attached C-16 fatty acid (palmitoyl) group. Specific amino acids are highlighted and an arrow indicates a connection between arginine and lysine residues.*

FDA Label Image

Image 02 (Image 02)

A line graph depicting Body Mass Index Standard Deviation Scores (BMI SDS) change from baseline over time (weeks) for two groups: Saxenda and placebo. The chart includes error bars representing standard error of mean, with Saxenda showing a decreasing trend in BMI SDS compared to stable values for placebo over 56 weeks, plus summary data at multiple time points.*

FDA Label Image

Image 4 (Image 04)

A data table displaying values organized by weight (in pounds and kilograms) across the top and height (in inches and centimeters) along the side. The table includes various numerical entries, with certain cells highlighted in gray and green, likely indicating specific ranges or categories related to the weight and height combinations.*

FDA Label Image

Image 65 (Image 05)

An illustration showing a smartphone with an arrow emerging from the screen pointing right, next to a QR code. This image appears to indicate scanning the QR code with a mobile device.*

FDA Label Image

Figure A (Image 08)

An instructional illustration depicting hands holding a pen-like injector device, pulling a protective cap away from the tip, indicated by an arrow showing the direction of removal. This image is likely part of usage instructions for Saxenda (liraglutide) injection solution.*

FDA Label Image

Image 09

Two side-by-side cumulative frequency graphs showing the percentage change in body weight for Saxenda (liraglutide) 6 mg/mL injection solution compared to placebo. The x-axes represent the percent change in body weight, and the y-axes represent cumulative frequency (%). Both graphs include separate lines for Saxenda (solid purple) and placebo (dashed gray), illustrating the distribution of body weight changes in study populations using multiple imputations (MI).*

FDA Label Image

Image 10

Two line graphs showing change in body weight percentage over 56 weeks for Saxenda (liraglutide) 6 mg/mL injection solution versus placebo. The left graph depicts a larger patient group with 2487 Saxenda and 1244 placebo subjects; the right graph shows a smaller group. Both graphs show Saxenda leads to greater body weight reduction compared to placebo over the study duration.*

FDA Label Image

Figure B (Image 11)

An instructional illustration showing a close-up of a hand holding a purple injection pen or syringe, highlighting the device used for subcutaneous injection of Saxenda (liraglutide) 6 mg/mL solution.*

FDA Label Image

Image 12

A line graph showing the change in body weight percentage over weeks for Saxenda (liraglutide) 6 mg/mL injection compared to placebo. The graph tracks body weight changes from -12 to 56 weeks, indicating greater weight loss with Saxenda after the start of a low-calorie diet around week 0. Patient numbers for each group at multiple time points are shown below the x-axis. The vertical axis represents percentage change in body weight.*

FDA Label Image

Note (Image 45)

Saxenda injection solution 6 mg/mL in a 3 mL prefilled pen, labeled for subcutaneous use. The packaging displays the brand name Saxenda and the generic ingredient liraglutide. The labeler is A-S Medication Solutions, and the product NDC is 50090-4257.*

FDA Label Image

Device (Image 47)

An illustrated diagram showing components of the Saxenda injection pen with labeled parts including pen cap, pen scale, pen window, dose counter, dose pointer, dose selector, and dose button. It also depicts needle components for NovoFine and NovoTwist, each including outer needle cap, inner needle cap, needle, and paper tab, along with a flow check symbol.*

FDA Label Image

Figure C (Image 48)

An instructional illustration showing how to attach a NovoFine or NovoTwist needle to a device. The image is divided into two sections, each with an arrow indicating the direction to twist the needle for proper attachment using fingers.*

FDA Label Image

Figure D (Image 49)

Illustration showing step D in an injection process for a medication pen. The first image depicts pressing a button or cap on the pen with a finger, and the second image shows twisting or turning an element on the pen as indicated by curved arrows. Likely instructions for preparing the pen before injection.*

FDA Label Image

Figure E (Image 50)

An instructional illustration showing a two-step process involving a pen-style injection device. The first step depicts removing a protective cap from the needle, followed by the second step depicting attaching a needle cap or cover. The image uses simple arrows to indicate the removal and attachment directions.*

FDA Label Image

Note (Image 51)

Saxenda 6 mg/mL injection solution in a 3 mL prefilled pen cartridge. The label shows the brand name Saxenda, active ingredient liraglutide, and indicates subcutaneous use. The labeler is A-S Medication Solutions. The packaging is primarily white with detailed product information printed in black and orange. The NDC number 50090-4257 is displayed on the label.*

FDA Label Image

Information (Image 52)

Saxenda 6 mg/mL injection solution in a subcutaneous use vial, labeled by A-S Medication Solutions. The vial has a clear glass body with a purple-colored cap and a label displaying product information including the proprietary name Saxenda, strength 6 mg/mL, and the NDC 50090-4257. The label includes visual and textual elements consistent with a prescription drug injection packaging.*

FDA Label Image

Figure F (Image 53)

Instructional illustration showing the final steps to attach a cap to a pen injector device. The left panel depicts a hand aligning and pressing the cap onto the device; the right panel shows the cap fully attached. The images guide proper assembly or closure of the injection pen.*

FDA Label Image

Flow Check Symbol (Image 54)

Saxenda 6 mg/mL injection solution in a 3 mL multiple-dose vial. The label shows liraglutide as the active ingredient and indicates subcutaneous use. The product is labeled by A-S Medication Solutions with NDC 50090-4257.*

FDA Label Image

Figure G (Image 55)

An instructional illustration showing a close-up of a hand holding a Saxenda injection pen with a flow check symbol selected, highlighting the process to confirm flow before injection. A zoomed inset displays the flow check symbol on the device.*

FDA Label Image

Note (Image 56)

Saxenda 6 mg/mL injection solution for subcutaneous use, presented in a carton. The label indicates the product is by A-S Medication Solutions and the package contains 3 multi-dose prefilled pens. The proprietary name Saxenda and the active ingredient liraglutide are visible on the front of the carton.*

FDA Label Image

Information (Image 57)

Saxenda 6 mg/mL injection solution for subcutaneous use in a multi-dose pen. The label shows the proprietary and generic names (liraglutide), strength, dosage form, and is labeled by A-S Medication Solutions. The carton design includes branding and instructions for patient use.*

FDA Label Image

Figure H (Image 58)

An instructional illustration showing a hand holding a Saxenda (liraglutide) 6 mg/mL injection pen. The image depicts the action of removing a cap or preparing the pen for use, indicated by a blue arrow pointing upward, highlighting the subcutaneous injection device's proper handling.*

FDA Label Image

Note (Image 59)

Saxenda 6 mg/mL injection solution label for subcutaneous use. The label indicates the product is manufactured by A-S Medication Solutions. The text and layout emphasize the proprietary name Saxenda and the generic name liraglutide, with key information about dosage strength and administration route.*

FDA Label Image

Information (Image 60)

Saxenda 6 mg/mL injection solution in a multi-dose pen carton, a subcutaneous human prescription drug by A-S Medication Solutions. The packaging prominently displays the brand and generic names along with strength and dosage form details.*

FDA Label Image

Figure I (Image 61)

An instructional diagram showing a dose selector on a Saxenda (liraglutide) injection pen. It illustrates how to set the dose by turning the dial, with an example displaying a 0.6 mg dose selected on the 6 mg/mL injection device.*

FDA Label Image

Information (Image 62)

Saxenda 6 mg/mL injection solution label for subcutaneous use. The label shows the proprietary name Saxenda and the generic name liraglutide. The product is labeled as a human prescription drug and is manufactured or distributed by A-S Medication Solutions. The label includes dosage strength of 6 mg/mL and the NDC 50090-4257.*

FDA Label Image

Figure J (Image 63)

An illustration showing a close-up view of a syringe with a purple dosage scale labeled from 3 to 6 and a white plunger. The syring is labeled with text indicating that approximately 3 mg of medication remains. It appears to be an instructional graphic related to measuring or estimating the remaining dose in the syringe.*

FDA Label Image

Information (Image 64)

Saxenda 6 mg/mL injection solution for subcutaneous use by A-S Medication Solutions. The white and green label displays the product name Saxenda prominently at the top, with liraglutide as the active ingredient indicated below. The vial pictured is a clear glass container with a gray rubber stopper and a metal seal. The label includes dosage strength and manufacturer information.*

FDA Label Image

Note (Image 65)

Saxenda 6 mg/mL injection solution for subcutaneous use in a prefilled pen. The label shows the proprietary name Saxenda with the generic name liraglutide. The labeler is A-S Medication Solutions. The packaging indicates it is a prescription drug with dosage and administration details likely included on the label.*

FDA Label Image

Figure K (Image 66)

Illustration showing the dose counter on a Saxenda injection pen, highlighting an example where the counter stops at 2.4 mg, indicating the remaining dosage during subcutaneous administration of liraglutide 6 mg/mL.*

FDA Label Image

Figure L (Image 67)

An instructional illustration showing a hand holding an injection pen vertically with the needle pointing downward, positioned above an arm. A downward arrow indicates the direction for administering a subcutaneous injection using the pen.*

FDA Label Image

Figure M (Image 68)

An instructional illustration showing a hand holding a Saxenda injection pen with an arrow indicating a downward pressing motion. A close-up inset highlights the dose display set to 0 mg, demonstrating dose setting or injection preparation for the liraglutide 6 mg/mL subcutaneous solution.*

FDA Label Image

Figure N (Image 69)

An instructional illustration showing a hand holding a Saxenda injection pen, with a speech bubble instructing to count slowly from 1 to 6. The illustration appears to guide the user on the timing or pacing of an action related to the injection.*

FDA Label Image

Note (Image 70)

Saxenda 6 mg/mL injection solution for subcutaneous use, labeled by A-S Medication Solutions. The product carton includes dosage instructions with a dosing pen illustration and dosage increments, emphasizing the titration schedule from 0.6 mg to 3.0 mg doses.*

FDA Label Image

Information (Image 71)

The packaging label for Saxenda 6 mg/mL injection solution shows a multi-dose pen containing liraglutide for subcutaneous use. The label features the Saxenda brand name prominently, with strength and dosage form indicated. The labeler is A-S Medication Solutions, and the label includes usage and storage information.*

FDA Label Image

Figure O (Image 72)

An instructional illustration showing a pen injector, likely for Saxenda (liraglutide) injection, with an arrow pointing upward indicating the direction to pull or extend a part of the device, possibly to prepare it for use.*

FDA Label Image

Figure P (Image 73)

Illustrations showing two types of injection pen needles used with Saxenda liraglutide injection: NovoFine and NovoTwist. The diagrams depict how to attach each needle type to the pen, with directional arrows indicating the twist or push motion for attachment.*

FDA Label Image

Figure Q (Image 74)

An instructional diagram showing the connection of a needle or pen device to a vial or cartridge, with an arrow indicating the attachment or insertion step. The illustration is likely part of preparation or administration instructions for a medication, possibly for subcutaneous injection.*

FDA Label Image

Figure R (Image 75)

Illustration showing hands holding and twisting a capped pen device, indicating the step of removing or attaching a pen cap. The image includes an arrow suggesting the direction of rotation, with the letter 'R' highlighted in a blue box at the top left corner.*

FDA Label Image

Information (Image 76)

Saxenda 6 mg/mL injection solution in a multi-dose vial packaging. The label displays the brand name Saxenda prominently, with liraglutide as the active ingredient for subcutaneous use. The labeler is A-S Medication Solutions, and the product NDC 50090-4257 appears on the packaging.*

FDA Label Image

Note (Image 77)

The image shows the carton packaging of Saxenda 6 mg/mL injection solution for subcutaneous use. The label displays the brand name Saxenda prominently, the generic name liraglutide, and indicates it is a human prescription drug. The package is labeled with the strength 6 mg/mL. The labeler is identified as A-S Medication Solutions, and the NDC code 50090-4257 is visible.*

FDA Label Image

Information (Image 78)

Saxenda 6 mg/mL injection, solution for subcutaneous use in a multi-dose pen. The label displays the brand name Saxenda prominently with the active ingredient liraglutide, and indicates the product is marketed by A-S Medication Solutions. Packaging information includes dosage form and route of administration.*

FDA Label Image

Figure S (Image 79)

An instructional illustration showing a close-up of a cap being removed from the end of a liraglutide injection pen, indicated by directional arrows pointing away from the pen and the cap.*

FDA Label Image

Note (Image 80)

Saxenda 6 mg/mL injection solution for subcutaneous use in a 3 mL prefilled pen. The packaging includes a white and red box with the product name, strength, and manufacturer A-S Medication Solutions displayed. The box also features a depiction of the injection pen and dosage instructions on the side.*

FDA Label Image

Label Image (Lbl500904257)

Saxenda (liraglutide) injection, 6 mg/mL, subcutaneous solution by A-S Medication Solutions. The label shows the NDC 50090-4257-0 with product number 9908-0, indicating use in 5 prefilled pens, each with 3 mL. The label includes storage instructions to refrigerate, avoid freezing, and protect from light.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.